Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectiveness – Renal and Urology News
Eli Lilly says government is continuing a separate study testing the antibody drug in mild to moderately ill patients.
Eli Lilly says government is continuing a separate study testing the antibody drug in mild to moderately ill patients.
The approval was based on data from 3 clinical trials: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02.
Researchers identified inflammatory subgroups in sepsis and assessed their association with previously described transcriptomic subphenotypes.
Considerations include holding medication on day or week of surgery/procedure in case of daily or weekly dose
Findings are based on a systematic review and meta-analysis of 25 trials involving 26,478 patients with chronic kidney disease (CKD) with or without dialysis.
Although viral infection is a potential cause of painful interstitial cystitis, few previous studies have examined antiviral treatment.
Researchers assessed the incidence and predictors of complications in patients with gram-negative bloodstream infections.
Researchers sought to determine whether rusfertide would be effective in patients with polycythemia vera.
Investigators assessed potential causal links between certain microbial genera and the risks for hyperuricemia and gout using Mendelian randomization methods.
Researchers assessed treatment response patterns and percentages over 52 weeks among patients with lupus nephritis receiving standard of care therapy.
Examination of joint links between polygenic risk scores and radiotherapy show more than additive increases in risk for some cancers